Literature DB >> 31136181

Pulmonary Dissolution of Poorly Soluble Compounds Studied in an ex Vivo Rat Lung Model.

Johanna Eriksson1, Helena Thörn, Erik Sjögren1, Lisa Holmstén, Katarina Rubin, Hans Lennernäs1.   

Abstract

Many inhaled drugs are poorly water soluble, and the dissolution rate is often the rate-limiting step in the overall absorption process. To improve understanding of pulmonary drug dissolution, four poorly soluble inhalation compounds (AZD5423 (a developmental nonsteroidal glucocorticoid), budesonide, fluticasone furoate (FF), and fluticasone propionate (FP)) were administered as suspensions or dry powders to the well-established isolated perfused rat lung (IPL) model. Two particle size distributions (d50 = 1.2 μm and d50 = 2.8 μm) were investigated for AZD5423. The pulmonary absorption rates of the drugs from the suspensions and dry powders were compared with historical absorption data for solutions to improve understanding of the effects of dissolution on the overall pulmonary absorption process for poorly soluble inhaled drugs. A physiologically based biopharmaceutical in silico model was used to analyze the experimental IPL data and to estimate a dissolution parameter ( kex vivo). A similar in silico approach was applied to in vitro dissolution data from the literature to obtain an in vitro dissolution parameter ( kin vitro). When FF, FP, and the larger particles of AZD5423 were administered as suspensions, drug dissolution was the rate-limiting step in the overall absorption process. However, this was not the case for budesonide, which has the highest aqueous solubility (61 μM), and the smaller particles of AZD5423, probably because of the increased surface area available for dissolution (d50 = 1.2 μm). The estimated dissolution parameters were ranked in accordance with the solubility of the drugs, and there was good agreement between kex vivo and kin vitro. The dry powders of all the compounds were absorbed more slowly than the suspensions, indicating that wetting is an important parameter for the dissolution of dry powders. A wetting factor was introduced to the in silico model to explain the difference in absorption profiles between the suspensions and dry powders where AZD5423 had the poorest wettability followed by FP and FF. The IPL model in combination with an in silico model is a useful tool for investigating pulmonary dissolution and improving understanding of dissolution-related parameters for poorly soluble inhaled compounds.

Entities:  

Keywords:  inhalation; isolated perfused lung model; lung dissolution; pulmonary drug absorption; pulmonary drug delivery

Mesh:

Substances:

Year:  2019        PMID: 31136181     DOI: 10.1021/acs.molpharmaceut.9b00289

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  6 in total

Review 1.  iBCS: 1. Principles and Framework of an Inhalation-Based Biopharmaceutics Classification System.

Authors:  Jayne E Hastedt; Per Bäckman; Antonio Cabal; Andy Clark; Carsten Ehrhardt; Ben Forbes; Anthony J Hickey; Guenther Hochhaus; Wenlei Jiang; Stavros Kassinos; Philip J Kuehl; David Prime; Yoen-Ju Son; Simon Teague; Ulrika Tehler; Jennifer Wylie
Journal:  Mol Pharm       Date:  2022-05-16       Impact factor: 5.364

2.  Model-Informed Drug Discovery and Development in Pulmonary Delivery: Biopharmaceutical Pharmacometric Modeling for Formulation Evaluation of Pulmonary Suspensions.

Authors:  Tomás Sou; Fadi Soukarieh; Paul Williams; Michael J Stocks; Miguel Cámara; Christel A S Bergström
Journal:  ACS Omega       Date:  2020-09-22

Review 3.  Organic Cation Transporters in the Lung-Current and Emerging (Patho)Physiological and Pharmacological Concepts.

Authors:  Mohammed Ali Selo; Johannes A Sake; Carsten Ehrhardt; Johanna J Salomon
Journal:  Int J Mol Sci       Date:  2020-12-01       Impact factor: 5.923

4.  In vivo pharmacokinetic study of remdesivir dry powder for inhalation in hamsters.

Authors:  Sawittree Sahakijpijarn; Chaeho Moon; Zachary N Warnken; Esther Y Maier; Jennie E DeVore; Dale J Christensen; John J Koleng; Robert O Williams
Journal:  Int J Pharm X       Date:  2021-02-27

5.  Rational Development of a Carrier-Free Dry Powder Inhalation Formulation for Respiratory Viral Infections via Quality by Design: A Drug-Drug Cocrystal of Favipiravir and Theophylline.

Authors:  Si Nga Wong; Jingwen Weng; Ignatius Ip; Ruipeng Chen; Richard Lakerveld; Richard Telford; Nicholas Blagden; Ian J Scowen; Shing Fung Chow
Journal:  Pharmaceutics       Date:  2022-01-27       Impact factor: 6.321

6.  Drug Absorption Parameters Obtained Using the Isolated Perfused Rat Lung Model Are Predictive of Rat In Vivo Lung Absorption.

Authors:  Johanna Eriksson; Erik Sjögren; Hans Lennernäs; Helena Thörn
Journal:  AAPS J       Date:  2020-05-11       Impact factor: 4.009

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.